Association of serum urate levels with the development and mortality of cardiovascular diseases has been implicated for many years. This association has been usually more potent for women than for men. Allopurinol has been suggested effective in the management of patients with heart failure in several experimental and observational studies. These beneficial effects may be due to its inhibitory effects on the production of oxygen free radicals from xanthine oxidase, but not due to its urate-lowering effects, because vascular endothelial function of heart failure patients improved by taking allopurinol but not by a uricosuric drug, probenecid. A recent randomized double blind study, however, did not show any significant effects of oxypurinol on the prognosis of heart failure. The dose of oxypurinol used in this study was 600 mg, corresponding to an allopurinol dose of 81 mg, which might have been insufficient. This notion is based on the results of retrospective observational studies showing that > 300 mg allopurinol is more effective than lower doses. Another observational study suggested that treatment with allopurinol decreased hospitalization or death in heart failure patients with gout.
Implication of xanthine oxidase-inhibiting therapy for non-gouty conditions
Allopurinol has been suggested effective in the management of patients with heart failure in several experimental and observational studies. These beneficial effects may be due to its inhibitory effects on the production of oxygen free radicals from xanthine oxidase, but not due to its urate-lowering effects, because vascular endothelial function of heart failure patients showing that > 300 mg allopurinol is more effective than lower doses. Another observational study suggested that treatment with allopurinol decreased hospitalization or death in heart failure patients with gout.
A recent double-blind crossover study suggested that allopurinol may be effective in patients with angina pectoris. They showed that 600 mg allopurinol prolonged time to the appearance of ST-depression or chest pain during exercise as compared to placebo among patients with stable angina. These results implicate beneficial effects of xanthine oxidase-inhibition on the management of cardiovascular diseases.
